NCT00329030 2021-11-01BMTCTN0401National Heart, Lung, and Blood Institute (NHLBI)Phase 3 Completed224 enrolled 24 charts
NCT00268983 2017-01-09Comparison Of Rituximab Versus Tositumomab and Iodine I 131 Tositumomab (BEXXAR® Therapeutic Regimen) For Patients With Relapsed Follicular Non-Hodgkins LymphomaGlaxoSmithKlinePhase 3 Completed14 enrolled 20 charts
NCT00319332 2015-04-17A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic RegimenGlaxoSmithKlinePhase 3 Withdrawn